Alfuzosin

Alfuzosin

Clinical data
Pregnancy category	AU: B2 US: B (No risk in non-human studies)
Routes of administration	Oral
ATC code	G04CA01 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	49%
Protein binding	82%-90%
Metabolism	Hepatic (CYP3A4-mediated)
Elimination half-life	10 hours
Excretion	Fecal (69%) and renal (24%)
Identifiers
IUPAC name N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
CAS Number	81403-80-7
PubChem CID	2092
DrugBank	APRD00490
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H27N5O4
Molar mass	389.449 g/mol

WikiDoc Resources for Alfuzosin
Articles
Most recent articles on Alfuzosin Most cited articles on Alfuzosin Review articles on Alfuzosin Articles on Alfuzosin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Alfuzosin Images of Alfuzosin Photos of Alfuzosin Podcasts & MP3s on Alfuzosin Videos on Alfuzosin
Evidence Based Medicine
Cochrane Collaboration on Alfuzosin Bandolier on Alfuzosin TRIP on Alfuzosin
Clinical Trials
Ongoing Trials on Alfuzosin at Clinical Trials.gov Trial results on Alfuzosin Clinical Trials on Alfuzosin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Alfuzosin NICE Guidance on Alfuzosin NHS PRODIGY Guidance FDA on Alfuzosin CDC on Alfuzosin
Books
Books on Alfuzosin
News
Alfuzosin in the news Be alerted to news on Alfuzosin News trends on Alfuzosin
Commentary
Blogs on Alfuzosin
Definitions
Definitions of Alfuzosin
Patient Resources / Community
Patient resources on Alfuzosin Discussion groups on Alfuzosin Patient Handouts on Alfuzosin Directions to Hospitals Treating Alfuzosin Risk calculators and risk factors for Alfuzosin
Healthcare Provider Resources
Symptoms of Alfuzosin Causes & Risk Factors for Alfuzosin Diagnostic studies for Alfuzosin Treatment of Alfuzosin
Continuing Medical Education (CME)
CME Programs on Alfuzosin
International
Alfuzosin en Espanol Alfuzosin en Francais
Business
Alfuzosin in the Marketplace Patents on Alfuzosin
Experimental / Informatics
List of terms related to Alfuzosin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Alfuzosin (patient information)

Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xatral. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation or to patients who are taking medications known to prolong the QT interval.

External links

• Uroxatral (manufacturer's website)
• Alfuzosin (patient information)